Side-by-side · Research reference

HGH Fragment 176-191vsN-Acetyl Epitalon Amidate

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED28/59 cited

BAnimal-StrongHUMAN-REVIEWED12/45 cited

HGH Fragment 176-191

GH Fragment · Pre-Clinical

50%Weight gain reductionNg 2000

~26 minHalf-life (est.)

No IGF-1 ↑GH axis impact

SQ · IP (animal) · Oral (tested)

N-Acetyl Epitalon Amidate

Bioregulator Tetrapeptide · Khavinson School

10 passagesExtra divisionsKhavinson 2004

Telomerase+Enzyme inductionKhavinson 2003

4-AATetrapeptide

SQ · Variable protocols

01Mechanism of Action

Parameter

HGH Fragment 176-191

N-Acetyl Epitalon Amidate

Primary target

Beta-3 adrenergic receptors on adipocytesHeffernan 2001

DNA promoter regions (telomerase, RNA polymerase II, retinal genes)

Pathway

Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001

Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression

Downstream effect

Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation

Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003 Khavinson 2004

Feedback intact?

N/A — does not interact with GH/IGF-1 axis

—

Origin

Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability

Antibody development

Not reported in available studies

—

02Dosage Protocols

Parameter

HGH Fragment 176-191

N-Acetyl Epitalon Amidate

Animal dose (oral)

500 mcg/kg body weightNg 2000

Obese Zucker rats, 19 days.

—

Animal dose (IP)

Not specified (14-day chronic administration)Heffernan 2001

Obese mice, daily IP injection.

—

Human equivalent dose

Not established — no published human RCTs

—

Frequency

Once daily (animal models)

Not specified in candidate papers

Evidence basis

Animal studies only

In vitro human cell cultureKhavinson 2004 Khavinson 2003

Duration tested

14–19 daysHeffernan 2001 Ng 2000

—

Detection window

50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015

WADA-banned; anti-doping testing available.

—

Oral bioavailability

Demonstrated efficacy in animal oral administrationNg 2000

Potential for oral therapeutic development.

—

Standard dose

—

No standardized human dosing in indexed literature

In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.

Cell culture protocol

—

Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004

Cells made 10 extra divisions (44 passages total vs 34 in control).

Duration

—

Chronic treatment in aging culture

Sustained effect through late passages.

Modification stability

—

N-acetyl + C-amide caps enhance peptidase resistance

Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.

03Metabolic / Fat Loss Evidence

Parameter

HGH Fragment 176-191

N-Acetyl Epitalon Amidate

Primary fat target

Adipose tissue (general) — beta-3 AR mediated lipolysisHeffernan 2001

—

Weight gain reduction

50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000

Obese Zucker rats, 19 days oral administration.

—

Body fat reduction

Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001

—

Lipolytic activity

Increased adipose tissue lipolytic activityNg 2000

Direct measurement in treated animals.

—

Beta-3 AR expression

Upregulated β3-AR mRNA in obese mice to lean-comparable levelsHeffernan 2001

—

Insulin sensitivity

No adverse effect — euglycemic clamp confirmedNg 2000

Contrasts with intact hGH diabetogenic effects.

—

IGF-1 impact

No elevation — fragment does not activate GH/IGF-1 axis

—

Beta-3 AR dependency

Effect abolished in β3-AR knockout miceHeffernan 2001

Confirms β3-AR as primary mechanism.

—

Route of administration

Efficacy demonstrated via oral and IP routesNg 2000 Heffernan 2001

—

Human evidence

None published — pre-clinical only

—

04Side Effects & Safety

Parameter

HGH Fragment 176-191

N-Acetyl Epitalon Amidate

Insulin sensitivity

No adverse effects observed in euglycemic clamp (animal)Ng 2000

—

GH/IGF-1 axis

No activation — avoids diabetogenic effects of full GHNg 2000

—

Human safety data

Not available — no published human trials

Not available in indexed literature

Candidate papers describe in vitro and animal models only.

WADA status

Banned as performance-enhancing drugCox 2015

—

Metabolic profile

Six metabolites identified; CRSVEGSCG most stableCox 2015

Detection window implications for doping control.

—

Theoretical telomerase risk

—

Telomerase activation in somatic cells raises theoretical oncogenic transformation concern

In vitro observations

—

No cytotoxicity reported in human fetal fibroblast cultureKhavinson 2004

Absolute Contraindications

HGH Fragment 176-191

·Competitive athletes (WADA-banned)Cox 2015

N-Acetyl Epitalon Amidate

·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization

Relative Contraindications

HGH Fragment 176-191

·Absence of human safety data — experimental use only

N-Acetyl Epitalon Amidate

·Individuals with hereditary cancer syndromes or high genetic cancer risk

05Administration Protocol

Parameter

HGH Fragment 176-191

N-Acetyl Epitalon Amidate

1. Route

Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.

Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.

2. Frequency

Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.

Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.

3. Duration

Animal protocols: 14–19 days. Human duration not established — no published trials.

Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.

4. Storage

Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.

Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.

5. Detection

Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015

—

06Stack Synergy

HGH Fragment 176-191

— no documented stacks

N-Acetyl Epitalon Amidate

+ Thymalin

Moderate

View Thymalin →

Both are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.

Epitalon: Protocol not defined in indexed literature
Thymalin: Tissue-specific bioregulator · separate dosing
Rationale: Complementary transcriptional targets
Primary benefit: Dual-axis aging intervention: cellular senescence + immune restoration